Replies to post #11218 on RespireRx Pharmaceuticals Inc (RSPI)

[food4thought]

Aiming,
Again, I am only pointing out that the back up plan does not exist in the public eye which allows us to speculate. This is an extremely intelligent board and right now this board is all we have, at least until a conference call is issued. I am a business man that does not understand a majority of the technical jargon posted by Neuro and others, but from a business stand point I know where we stand, and we are standing in quicksand. If there is not a back up plan then Stoll certainly needs to depart and I prey for a buyout of technology. I just don't believe that someone exists to bail out a failing company, other than a value draining loan shark, no matter how great the technology. If there is no money in the bank what is it the technology seriously worth? Can our existing cash get us to point where there may again be BP interest?

[atheroprevent]

Why does this board expect BP buyout after the ADHD FDA return of CX 717 IND. The current SP reflects greater risk or lower likelihood of NDA for ampakines. Prior to IND return by the FDA, BP buyout seemed rational. Now it is wishful thinking.

I think buyout is off the table for this year, at least until COR can demonstrate a marketable signal of benefit in humans from ampakine administration in RD or AD.

If the AD trial remains free of adverse effect and demonstrates some early benefits in memory formation, which would allow patients to be managed at home longer, ampakines would be developed as a blockbuster. The ADHD door would reopen, hopefully sooner than the years that Neuro suggested.

I would love to see the spotlight remain on Pirosh as he reverses his prediction again. I don't know how Havrilla responded. He had predicted the highest likelihood of success for the IND.

I join the COR club, at the gold level (50K or more) of charitable giving for ampakine development. I continue to hold all of my shares.

Biotech investing is becoming an oxymoron in today's regulatory environment.

[enemem]

Aiming4, your evidence for COR management's foresight undercuts your claim. They raised cash under unfavorable terms, and it isn't enough to make much of a difference. The notion that inlicensing might bail the company out has been almost uniformly seen as an utterly foolish course of action, since development of an inlicenced drug would come at the cost of ampakine development.

I've deleted a lengthy disquisition on why COR is dead meat, since this isn't particularly helpful. The focus should instead be on what the company HAS to do, namely:

>Provide the investment community with a robust development timeline, for indications likely to gain approval by the FDA (i.e. orphan/neurodegenerative/short term) that can be executed with the funds available within a year.

>Jettison the compound by compound partnership model. The company needs to focus on bringing any ampakine to market for any indication, and to do this, it needs to provide bigger entities the incentives to establish a partnership. The most attractive candidate is likely AZ.

>The company needs to engage in buyout negotiations.

I think all three of these tasks need to be undertaken in parallel. Development of a feasible in-house clinical program will constrain the scope of any partnership deal, and buyout negotiations will provide leverage to establish partnerships under acceptable terms. By the same token, credible in-house and partnership proposals will increase the company's perceived value in the event that a buyout begins to take shape.

To the extent that the first or second tasks are impracticable, the third task should be undertaken, with some realism about the company's value.

Unless we're all delusional about the promise of ampakines, I think that there has to be a way forward.